查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1621752

血紅素病市場機會、成長促進因素、產業趨勢分析與預測 2024 - 2032

Hemoglobinopathies Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 165 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年，全球血紅蛋白病市場價值為 63 億美元，在血紅蛋白相關疾病的增加、遺傳研究的發展和新的治療發明的推動下，預計 2024 年至 2032 年的複合年成長率為 10.4%。血紅蛋白疾病包括鐮狀細胞疾病 (SCD) 和地中海貧血等遺傳性疾病，這些疾病會影響血紅蛋白的結構和功能，而血紅素是負責紅血球中氧運輸的蛋白質。該行業涵蓋這些遺傳性血液疾病的診斷、治療和管理，提供旨在緩解症狀和潛在治癒的藥物、基因療法、診斷測試和輸血服務。市場依疾病類型分為地中海貧血和 SCD 等類別，其中地中海貧血進一步分為 α 型和 BETA 型。

2023年，SCD佔據最大市場佔有率，價值33億美元。 SCD 的治療包括輸血、疼痛管理和羥基脲，基因療法和基於 CRISPR 的方法取得了有希望的進展。製藥業和政府資助的支持正在促進創新治療方案的開發。從治療類型來看，市場分為輸血、羥基脲、鐵螯合療法、骨髓移植等方法。

到 2023 年，輸血將佔據市場的 43.1%，並且仍然是一種重要的治療方法，特別是在地中海貧血和 SCD 等疾病中。該療法包括定期輸注健康紅血球，以緩解貧血、盡量減少併發症並改善患者的生活品質。輸血治療在發展中地區尤其重要，因為這些地區的先進治療方案可能不太容易取得。從地區來看，到 2032 年，北美的複合年成長率預計將達到 10%，市場規模預計將達到 57 億美元。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 63 億美元
預測值 153 億美元
複合年成長率 10.4%

美國血紅蛋白病市場的成長得益於意識的提高、早期診斷以及對 SCD 和地中海貧血等疾病的先進治療的採用。該地區強大的醫療基礎設施促進了尖端診斷技術的快速整合，包括基因療法和下一代定序。政府主導的舉措，例如新生兒篩檢計劃，也提高了早期檢測率，顯著提高了患者的治療效果。隨著對有效治療的需求不斷成長，以及政府和產業對先進療法的投資增加，血紅蛋白疾病市場必將大幅擴張。

這一成長與全球改善這些影響生命的血液疾病的診斷、治療和整體管理的努力相一致。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 血紅素病患病率增加
      • 診斷技術的進步
      • 新興基因療法與幹細胞移植
    • 產業陷阱與挑戰
      • 治療費用高
      • 與治療相關的副作用
  • 成長潛力分析
  • 監管環境
  • 管道分析
  • 未來市場趨勢
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按疾病類型，2021 - 2032

  • 主要趨勢
  • 地中海型貧血
    • α地中海貧血
    • BETA地中海型貧血
  • 鐮形血球貧血症
  • 其他疾病類型

第 6 章：市場估計與預測：按處理方式，2021 - 2032 年

  • 主要趨勢
  • 輸血
  • 羥基脲
  • 鐵螯合療法
  • 骨髓移植
  • 其他治療類型

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 醫院
  • 專科診所
  • 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 9 章：公司簡介

  • bluebird bio
  • Bristol-Myers Squibb Company
  • CHIESI FARMACEUTICI
  • Emmaus Medical
  • Medunik USA
  • Novartis
  • Pfizer
  • Prolong Pharmaceuticals
  • Teva Pharmaceuticals Industries
  • Vertex Pharmaceuticals Incorporated
簡介目錄
Product Code: 11866

The Global Hemoglobinopathies Market was valued at USD 6.3 billion in 2023 and is anticipated to grow at a CAGR of 10.4% from 2024 to 2032, driven by a rise in hemoglobin associated diseases, developments in genetic research, and new therapeutic inventions. Hemoglobinopathies encompass genetic conditions such as sickle cell disease (SCD) and thalassemia that affect the structure and function of hemoglobin, the protein responsible for oxygen transport in red blood cells. This industry spans the diagnosis, treatment, and management of these inherited blood disorders, offering pharmaceuticals, gene therapies, diagnostic tests, and blood transfusion services aimed at both symptomatic relief and potential cures. The market is segmented by disease type into categories like thalassemia and SCD, with thalassemia further divided into alpha and beta forms.

In 2023, SCD accounted for the largest share of the market, valued at USD 3.3 billion. Treatments for SCD include blood transfusions, pain management, and hydroxyurea, with promising advancements in gene therapy and CRISPR-based approaches. Support from the pharmaceutical sector and government funding is fostering the development of innovative treatment options. In terms of treatment type, the market is divided into blood transfusion, hydroxyurea, iron chelation therapy, bone marrow transplant, and other methods.

Blood transfusions represented a notable 43.1% of the market in 2023 and remain a crucial treatment, especially in conditions like thalassemia and SCD. This therapy involves the regular transfusion of healthy red blood cells to alleviate anemia, minimize complications, and improve patients' quality of life. Blood transfusion therapy is particularly vital in developing regions, where advanced treatment options may be less accessible. Regionally, North America is poised to grow at 10% CAGR through 2032, with the market expected to reach USD 5.7 billion.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$6.3 Billion
Forecast Value$15.3 Billion
CAGR10.4%

U.S. hemoglobinopathies market growth is supported by enhanced awareness, early diagnosis, and the adoption of advanced treatments for conditions like SCD and thalassemia. The region's strong healthcare infrastructure facilitates rapid integration of cutting-edge diagnostic technologies, including gene therapies and next-generation sequencing. Government-led initiatives, such as newborn screening programs, are also improving early detection rates, significantly boosting patient outcomes. With a growing demand for effective treatments and increased government and industry investment in advanced therapies, the hemoglobinopathies market is set for substantial expansion.

This growth aligns with global efforts to improve the diagnosis, treatment, and overall management of these life-impacting blood disorders.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of hemoglobinopathies
      • 3.2.1.2 Advancement in diagnostic technologies
      • 3.2.1.3 Emerging gene therapies and stem cell transplantation
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost associated with treatment
      • 3.2.2.2 Side effects associated with treatment
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Thalassemia
    • 5.2.1 Alpha thalassemia
    • 5.2.2 Beta thalassemia
  • 5.3 Sickle cell disease
  • 5.4 Other disease types

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Blood transfusion
  • 6.3 Hydroxyurea
  • 6.4 Iron chelation therapy
  • 6.5 Bone marrow transplant
  • 6.6 Other treatment types

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Specialty clinics
  • 7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 bluebird bio
  • 9.2 Bristol-Myers Squibb Company
  • 9.3 CHIESI FARMACEUTICI
  • 9.4 Emmaus Medical
  • 9.5 Medunik USA
  • 9.6 Novartis
  • 9.7 Pfizer
  • 9.8 Prolong Pharmaceuticals
  • 9.9 Teva Pharmaceuticals Industries
  • 9.10 Vertex Pharmaceuticals Incorporated